Corona Remedies
BSE: CORONA · Pharmaceuticals
Snapshot
Unlock Corona Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Corona Remedies is a pharmaceutical company focused on the development, manufacturing, and marketing of medicinal products. Its therapeutic portfolio spans women’s healthcare, cardiology, pain management, and urology.
Business Model
The company generates revenue through the sale of pharmaceutical formulations across various therapeutic segments. It operates as a manufacturer and marketer of healthcare products within the Indian market.
Growth Outlook
Growth is expected to be driven by the expansion of its therapeutic product offerings and continued penetration into the domestic pharmaceutical market.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players vying for market share in therapeutic segments like cardiology and pain management.
- Pricing Pressures. Government-imposed price controls on essential medicines can significantly impact profit margins for pharmaceutical manufacturers.
- Supply Chain Disruptions. Dependence on raw material suppliers for active pharmaceutical ingredients exposes the company to potential supply chain volatility.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Corona Remedies and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Corona RemediesCORONA | 9,638 | — | — | — | 21.0% | — | — | — |
Concord Biotech Ltd.CONCORDBIO | 10,890 | 54.32 | 33.52 | -12.1% | 39.8% | 13.9% | 18.0% | -26.8% |
Sanofi Consumer Healthcare India Ltd.SANOFICONR | 9,646 | 40.71 | 28.71 | 40.1% | 37.7% | 85.8% | 104.9% | -11.3% |
Strides Pharma Science LimitedSTAR | 8,494 | 17.39 | 10.36 | 4.9% | 22.1% | 21.4% | 23.5% | +14.3% |
Viyash ScientificVIYASH | 8,352 | 85.25 | 24.37 | 70.4% | 19.1% | 12.1% | 17.8% | — |
Procter & Gamble Health LimitedPGHL | 8,077 | 34.81 | 23.63 | 15.6% | 33.7% | 61.2% | 77.6% | +17.1% |
As of Mar 2026
Financials
Corona Remedies
BSE: CORONA · Pharmaceuticals
Snapshot
Unlock Corona Remedies's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Corona Remedies is a pharmaceutical company focused on the development, manufacturing, and marketing of medicinal products. Its therapeutic portfolio spans women’s healthcare, cardiology, pain management, and urology.
Business Model
The company generates revenue through the sale of pharmaceutical formulations across various therapeutic segments. It operates as a manufacturer and marketer of healthcare products within the Indian market.
Growth Outlook
Growth is expected to be driven by the expansion of its therapeutic product offerings and continued penetration into the domestic pharmaceutical market.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality control standards and evolving pharmaceutical regulations in India.
- Market Competition. The pharmaceutical sector is highly competitive, with numerous players vying for market share in therapeutic segments like cardiology and pain management.
- Pricing Pressures. Government-imposed price controls on essential medicines can significantly impact profit margins for pharmaceutical manufacturers.
- Supply Chain Disruptions. Dependence on raw material suppliers for active pharmaceutical ingredients exposes the company to potential supply chain volatility.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Corona Remedies and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026